UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

Advanced PET/CT imaging can improve long-term outcomes in recurrent prostate cancer, UCLA-led study finds

A five-year retrospective study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that prostate-specific membrane antigen PET/CT scans can help doctors target treatment more precisely for men whose prostate cancer returns after surgery, improving long-term outcomes and potentially reducing unnecessary side effects.

February 13, 2026

Vol.52 No.06

Clinical Roundup

Lab-grown organoids reveal how glioblastoma resists treatment

UCLA scientists have developed advanced miniature 3D tumor organoid models that make it possible to study glioblastoma tumors in a setting that closely mirrors the human brain, shedding light on how the aggressive cancer interacts with surrounding brain cells and the immune system to become more invasive and resistant to therapy.

January 30, 2026

Vol.52 No.04

Clinical Roundup

UCLA launches trial comparing two types of PSMA radiopharmaceuticals for recurrent prostate cancer

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether combining precision radiation with a targeted radioactive therapy drug can help patients with recurrent prostate cancer delay progression, while delaying or avoiding the side effects of long-term hormone therapy.

January 30, 2026

Vol.52 No.04

Drugs & Targets

Personalis Real-Time Variant Tracker identifies resistance mutations across several hundred clinically relevant hotspots

Personalis announced the early access launch of Real-Time Variant Tracker, a powerful new option added to its ultrasensitive NeXT Personal molecular residual disease test designed to detect small traces of circulating tumor DNA in the blood that represent residual or recurrent cancer.

January 23, 2026

Vol.52 No.03

Clinical Roundup

Off-the-shelf immunotherapy produces deep and durable responses in extramedulary MM, Mayo researchers find

A Mayo Clinic study published in the New England Journal of Medicine demonstrates that an off-the-shelf, dual-antibody therapy can generate deep and durable responses in extramedullary multiple myeloma—one of the most aggressive and treatment-resistant forms of the disease.

December 12, 2025

Vol.51 No.45

In Brief

UCLA Health launches Department of Nuclear Medicine and Theranostics

UCLA Health has established the Department of Nuclear Medicine and Theranostics—the first of its kind in the United States. The new department will integrate advanced imaging and therapy, accelerate scientific discovery, and advance precision health at UCLA Health.

November 21, 2025

Vol.51 No.43

UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

YOU MAY BE INTERESTED IN

Advanced PET/CT imaging can improve long-term outcomes in recurrent prostate cancer, UCLA-led study finds

Lab-grown organoids reveal how glioblastoma resists treatment

UCLA launches trial comparing two types of PSMA radiopharmaceuticals for recurrent prostate cancer

Personalis Real-Time Variant Tracker identifies resistance mutations across several hundred clinically relevant hotspots

Off-the-shelf immunotherapy produces deep and durable responses in extramedulary MM, Mayo researchers find

UCLA Health launches Department of Nuclear Medicine and Theranostics

Renew today!

Subscriber content

Never miss an issue!

Login